Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role.
Overview
Airway remodeling (AR) can be collectively considered a process encompassing changes in structural cells and tissues of the airway in obstructive disease (particularly asthma). The last two decades have witnessed a profound, progressive increase in AR research (Table 1) , with appreciation that AR is part of the pathogenesis and a cardinal feature of chronic airway disease. Unfortunately, numerous factors have thwarted our ability to understand AR pathology and mechanisms and to address it clinically. In this Research Statement, we discuss specific scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR, and we propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Indeed, unlike scientific review articles that typically summarize research findings on a scientific theme, an American Thoracic Society (ATS) Research Statement provides a more appropriate platform for articulating the challenges-scientific, logistical, and monetary-of advancing specific research and its clinical application as well as providing recommendations for addressing these challenges.
Specific Challenges for Enabling AR Research and Advancing AR Therapeutics
d Lack of consensus regarding the importance of multiple features of AR.
Although numerous airway cell types and processes are involved in AR, a majority of studies have focused on a subset of features (Table 1) or simply noted the existence of AR-relevant changes in different disease models, with some attempts to implicate specific effectors. Importantly, the pathophysiological role of specific AR indices in more well-accepted asthma features (airway hyperreactivity [AHR] , airway impedance independent of AHR, or inflammation) is largely conceptual and associative/correlative but does not demonstrate necessity and sufficiency of AR in disease, leading to lack of clear direction and rationale for AR research, identification of therapeutic targets, and development of anti-AR drugs ( Interest in AR research and its clinical relevance, particularly with respect to asthma, increased dramatically in the early 1990s, as evidenced by a significant increase in peer-reviewed publications (680 reviews alone among 2,430 peer-reviewed publications since z1995) ( Table 1) . Multiple studies and review articles posit AR as a principal cause of irreversible airway obstruction and the therapyresistant component of AHR, noting the association of AR and rapid decline in lung function in individuals with severe asthma and modeling that predicts the effect of airway wall remodeling on airflow obstruction (24) (25) (26) (27) (28) . This interest in AR has been maintained over the last 2 decades, as indicated by relevant publications, particularly in the context of asthma (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . However, an important caveat is that a majority of studies have used multiple models and systems (in vivo, ex vivo, and in vitro preclinical models using different species, including human and animal airway tissue-and cell-based studies) to further characterize AR and the mechanisms driving it. Specific to the human condition, the longitudinal and progressive nature of AR contrasts with the largely cross-sectional nature of most ARfocused studies in human asthma, thus severely limiting our understanding of the likely multiple cell types and mechanisms that contribute to AR and allowing only predictions about whether current or emerging therapies can impact AR. Nonetheless, studies to date reflect a general, albeit not unanimous, consensus that AR contributes significantly to the pathology of asthma and other obstructive lung diseases and is an important therapeutic target. However, despite sustained enthusiasm among the research community for this topic, little if any progress has been made in developing therapeutics that inhibit or reverse AR. Here, it is important to emphasize that current therapies targeting asthma that help alleviate other key aspects of asthma, AHR and inflammation, are largely ineffective in addressing AR, whereas therapy-resistant aspects of AHR may further represent AR (16, (29) (30) (31) (32) (33) (34) (35) (36) (37) .
This Research Statement attempts to examine the underlying barriers to progress in AR research and development of therapeutics. Of note, this Research Statement is not intended to provide any clinical guidelines or recommendations for treatment of AR or any obstructive lung disease but rather to provide direction regarding how to better advance AR research and the development of therapeutic strategies that address it. For practical purposes, this Research Statement will focus on AR that occurs with asthma, although many of the issues raised and recommendations proposed are applicable to AR in other obstructive lung diseases.
Methods

Committee Composition and Meetings
The project organizers invited an international, multidisciplinary group with expertise relevant to the main objectives of the project. Accordingly, the group was composed of bench and clinical researchers with expertise in AR in various diseases in various populations, industry representatives with experience in drug development and regulatory approval of drugs, and program officials from the NIH (lung biology programs of the NIA and NHLBI).
Two separate meetings were held. The first meeting was conducted in March 2015 using the web-based forum "Chatter" (www.salesforce.com/chatter) and facilitated by ATS support staff. In this meeting, participants discussed and refined the objectives of the ATS Project and identified key talking points that were used by the project organizers to generate and disseminate an agenda for a subsequent face-to-face meeting at the 2015 ATS International Conference in Denver, Colorado. Participants at the ATS meeting arrived at a general consensus regarding the issues that currently face the advancement of AR research and therapeutics and discussed various strategies for addressing these issues. The Project Organizers reviewed the discussions from the two meetings, performed a literature search as described below, and collectively wrote the Research Statement. Participants disclosed all potential conflicts of interest, which were vetted and managed in accordance with the policies and procedures of the ATS.
Literature Search and Appraisal of Existing Evidence
Each of the authors performed a PubMed search related to specific topics. The results were shared among all authors and additional references, where appropriate, were identified. The literature search conducted for this Research Statement was not a systematic review of the evidence, given the broad definition of AR, lack of preclinical or clinical/human data on the many factors influencing AR, and limited longitudinal studies in humans.
Document Development
Project organizers identified two leaders who prepared a draft document on the basis of the web and in-person discussion and contributions from the members of the writing group. These leaders collated, organized, and formatted a complete single document that was sent to all participants for review and feedback. After multiple cycles of revision, review, and feedback until all participants agreed on a version of the draft, the document was finalized for submission.
The Problem: Advancing AR as a Mechanistic Focus and Therapeutic Target AR can be collectively considered as a process encompassing changes in the structural cells and tissues of the obstructive diseased airway (particularly asthmatic airways) (38) (39) (40) (41) (42) (43) (44) (45) (46) . Although AR studies differ in characteristics of patient population, such as age, disease definition AMERICAN THORACIC SOCIETY DOCUMENTS severity and duration, atopy, smoking history, and the types of tissues analyzed (e.g., whole lung samples from autopsies versus bronchial biopsies), what is most relevant to this report, and part of what makes AR difficult to study, is the many histological features noted in the AR response. These include airway wall thickening, airway edema, subepithelial fibrosis, epithelial hyperplasia with mucus metaplasia, airway smooth muscle (ASM) hyperplasia and hypertrophy, and the increased presence of myofibroblasts and inflammatory cells. The questions then become: (1) What mechanisms underlie initiation, maintenance, and progression of these various aspects of AR? (2) How do these AR elements contribute to the AHR of asthma, disease progression, and severity? (3) How does AR contribute to individual and age-related differences in asthma symptomatology? and (4) Are current therapeutic approaches effective in blunting or reversing AR, and, if not, what are the most promising alternative strategies?
All structural components of the airway wall have been reported to be thickened in asthma (47) (Figure 1) , with the extent of thickening worsening with disease severity, but importantly, with different contributions of the small (,600 mm) and mid-sized (1-3 mm) airways in nonfatal asthma versus larger membranous airways in fatal asthma (48) (49) (50) (51) (52) (53) . Here, the role of the airway epithelium as a recipient of asthma triggers, in the initial and sustained immune response of asthma, as well as a key aspect of AR are recognized, the latter involving epithelial layer thickening, mucous metaplasia, and subepithelial fibrosis (54) (55) (56) . The role of ASM in AR is also being increasingly recognized, with hyperplasia and hypertrophy of this cell type contributing to wall thickness and AHR and, in addition, ASM being a source of extracellular matrix (ECM), and of growth factors and cytokines that promote inflammation and AR itself (22, 32, 57) . Certainly, fibroblasts can contribute to AR via increased ECM production, although their role is perhaps less well explored in the context of asthma (18, 58) . Conversely, ECM components can influence cellular behavior, such as proliferation and migration. Finally, there is increasing recognition that enhanced airway vascularity is an important aspect of AR, highlighting the potential role of angiogenic factors and, furthermore, interactions between airways and vasculature (59, 60) . Downstream, hyperinflation and air trapping occur consequent to these structural changes in the bronchial airway, leading to well-recognized features in radiographic images. The relevance of the different cell types and the consequences of AR lies in the potential for identifying targets for AR therapy and, conversely, alleviation of AR effects as indicators of therapeutic efficacy.
However, an important hindrance to AR as a major focus in asthma research is that the physiologic and clinical consequences of wall thickening are not well understood, despite studies suggesting that increased wall thickness correlates with disease severity (61) (62) (63) (64) (65) (66) . Here, modeling and imaging evaluations are consistent with the intuitive idea that airway thickening enhances the extent of luminal closure for a specific extent of airway contraction, thus contributing to the AHR of asthma. Conversely, outer wall thickening could alter the relationships between tethering forces of the airway and luminal closure, affecting dynamic mechanical properties of the airways that promote their collapse (3, 67) . Thus, the link between wall thickening and AHR drives the essential goal of understanding the cell types and mechanisms that contribute to structural changes within the airway and the need to target cells or pathways that contribute to functional changes in asthma.
The role of the epithelium in AR is not in doubt (11, 54, (68) (69) (70) (71) (72) (73) (74) , with mucus hypersecretion and metaplasia and epithelial hypertrophy leading to mucus plugging of the bronchial lumen. Subepithelial mucus-secreting glands are increased in fatal and nonfatal asthma (75, 76) , as is epithelial area within the Here, well-recognized allergic, infectious, and environmental factors can play a role. In addition, there is increasing evidence that agonist-induced bronchoconstriction and the associated mechanical forces acting on the airway can trigger changes to the airway. Asthma induction leads to a sustained cycle of chronic inflammation, cell-cell interactions, and secreted factors (from both immune cells and structural cells of the airway), leading to chronic disease characterized by airway hyperresponsiveness and a multitude of structural changes to the airway that represent AR. Here, AR includes changes to epithelial thickness, composition (greater proportion of mucus-producing cells), thickening and fibrosis of the underlying lamina propria, increased numbers and size of airway smooth muscle cells, increased presence of fibroblasts and altered extracellular matrix (ECM) composition, and increased microvasculature in the asthmatic airway wall. ASM = airway smooth muscle.
asthmatic airways (24) , leading to changes in luminal diameter. Furthermore, changes in mucus properties can modulate the effects of airway shortening and surface tension at the air-liquid interface, leading to greater airway narrowing. In terms of subepithelial fibrosis, it appears that increased fibrotic responses within the lamina reticularis are particularly relevant (4, 42, 44, (77) (78) (79) , characterized by accumulation of ECM elements such as fibronectin, various collagens, and matrix metalloproteinases (38, (80) (81) (82) (83) (84) (85) . Some studies have associated subepithelial fibrosis with asthma severity and changes in FEV 1 (63, (86) (87) (88) as well as sensitivity to methacholine challenge (i.e., AHR) (89), but others do not find a correlation (90) . Therefore, fibrosis may promote or act as a marker for AHR, although the link is not well established, given its presence even in mild asthma (79) and conversely lack of correlation with asthma severity in some studies (90, 91) . Furthermore, increases in sub-basement membrane fibrosis can occur to comparable levels in subjects with allergic rhinitis and in asthma. Therefore, the physiological relevance of such fibrosis remains unknown. Conversely, basement membrane thickening can occur early in lung development/growth as well as before AHR and symptoms (92) (93) (94) (95) (96) , suggesting that fibrosis is a biomarker for ongoing biological processes and risk for AR that eventually does affect lung function. Along similar lines, an increase in ASM mass has been demonstrated in some studies (41, 62, 72, (97) (98) (99) (100) (101) , with evidence for both hyperplasia and hypertrophy, although the contribution of either mechanism to AHR per se is not established. Furthermore, the presence of myofibroblasts has been reported in asthma (102) (103) (104) (105) , although their origin and eventual differentiation are a topic of debate (106) (107) (108) . Thus, overall, a number of cell types/layers can contribute to AR, with either variable or unclear contributions to AHR. In this regard, the relative roles of these cell types in different age groups and disease-specific contexts (atopy, infections, environmental exposures) are a major topic of ongoing investigation. AR can appear early in disease, as suggested by airway changes in pediatric asthma (92) (93) (94) (95) (96) . However, given that such remodeling is already present by the time of patient presentation, and bronchial samples are unlikely to be obtained early for disease diagnosis or in a serial fashion, much of the information regarding AR induction is speculative and generated in studies using animals or reductionist cell-based experiments. Accordingly, what induces AR in the human is not well defined. Certainly, the inflammatory cascade initiated by asthma triggers can influence every cell type that contributes to AR. Thus, a major confounding factor is the concurrent presence of chronic and/or acute inflammation that likely influences remodeling. Indeed, the plethora of inflammatory mediators that influence various aspects of AR is ever increasing (5, 22, 44, 104, (109) (110) (111) (112) , further compounded by the immunomodulatory capabilities of structural airway cells (40, 102, 113, 114) . The importance of understanding mechanisms in early and persistent AR further lies in the recognition that current pharmacological therapies for established asthma, such as corticosteroids, are largely ineffective in alleviating AR (16, 63, 69, (115) (116) (117) (118) ; although emerging interventions such as bronchial thermoplasty appear to locally alleviate AR (119, 120) , there continue to be no approaches for global targeting of AR in the obstructed lung.
Interestingly, recent studies demonstrate the potential for disease in which airway inflammation is uncoupled from AHR (121) (122) (123) , underscoring the complexity of this latter phenomenon and highlighting the potential role for AR as a contributory rather than consequent factor in asthma diathesis. Accordingly, it becomes important to define what AR per se encompasses, what factors contribute to AR, and how these factors can be therapeutically targeted to alleviate structural and functional changes in airway diseases.
A fundamental feature of AR is its longitudinal and progressive nature (although there is some evidence that ASM thickness may be related more to asthma severity than duration [124] ). However, longitudinal studies unfortunately remain limited in scope and number, typically involve only larger airways (where disease manifestation may be variable) (125) (126) (127) (128) (129) (130) (131) , and are often confounded by ongoing therapy. Thus, studies of asthmatic airway structure have tended to be cross-sectional in nature and may not encompass the disease spectrum. Overall, the question of whether AR is a separate process in asthma, a consequence of the persistent inflammation or of other ongoing insults, remains to be established but is of obvious and considerable relevance to understanding both the pathogenesis and treatment of asthma.
Given the increasing recognition of the importance of AR in asthma pathogenesis and symptoms, a fundamental unmet clinical and research need is therapeutic targeting of remodeling. Although some studies using animal models suggest certain drugs may prevent the development of AR concomitant with allergic lung inflammation and AHR (132) (133) (134) (135) (16, 63, 69, (115) (116) (117) (118) . Thus, it is tempting to propose that with long-term disease, the eventual refractoriness to therapy and lack of improvement in lung function in individuals with asthma may reflect fixed airway obstruction resulting from AR. Consequently, if AR is of pathophysiological significance, even patients with "well-controlled" asthma will suffer a progressive loss of lung function and increased fixed airway resistance, and thus even this population is in need of improved therapy. Importantly, AR features render current asthma therapies even less effective in regulating airway resistance and improving airflow. Accordingly, targeting AR represents an opportunity for early intervention in asthma, an approach that would address a major, unmet clinical need.
Despite the importance of AR to asthma pathophysiology, several factors deter the development of therapies that prevent or treat AR. An obvious factor is the longitudinal and ill-defined nature of AR that necessitates long-term investment in AR research that is economically prohibitive in nature (particularly in the current federal funding environment) and furthermore leads to regulatory issues relevant to the development and approval of AR drugs.
Specific Issues That Hinder AR Research
There are intrinsic characteristics of AR research that render it difficult to perform.
THERE ARE MULTIPLE FEATURES OF AR AND A LACK
OF CONSENSUS REGARDING WHICH ARE IMPORTANT.
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As noted above, alterations in the morphology or function of numerous airway cells can contribute to AR, particularly epithelial cells, ASM, fibroblasts, and even infiltrating immune cells, with the additional contribution of ECM components, inflammatory mediators, and even vasculogenesis. A majority of AR studies have focused on changes in ASM mass, thickening of the lamina propria, increased matrix deposition, or mucous metaplasia. Although in one sense these studies have substantially advanced the AR field, most research has simply noted the existence of AR-relevant changes associated with human asthma or murine models of asthma (typically allergic lung inflammation), and some studies have attempted to implicate specific effectors. Moreover, the causative role of various indices of AR in the well-accepted features of asthma, such as AHR, increased airway impedance (independent of AHR), or increased airway inflammation itself, is largely conceptual and based on association/correlation data. The inability to specifically manipulate AR features to demonstrate their requirement/sufficiency in asthma (or other obstructive lung diseases) means definitive proof of their pathogenic roles is lacking. This equivocation and uncertainly over the extent to which different features of AR are functionally important translates into a lack of direction for the AR field and lack of a clear rationale for pursuing and designing translational and clinical research that would help alleviate AR.
THERE ARE FUNDAMENTAL METHODOLOGIC LIMITATIONS IN PERFORMING AR
RESEARCH. Fundamental methodological limitations in performing AR research include (1) a lack of relevant models, (2) the longitudinal and slow-developing nature of AR, (3) difficulty in accessing or accurately measuring critical indices, and (4) prohibitive expenses relating to its longitudinal nature and the associated costs of sensitive and specific techniques necessary to identify/quantify AR.
MODEL SYSTEMS. Although much of preclinical asthma research embraces the murine model (typically of allergic lung inflammation), especially given the ease of manipulating the mouse genome, there are also well-known limitations of the mouse "asthma" model (136) (137) (138) (139) (140) (141) (142) (143) (144) (145) . The most relevant limitations include an immune response to allergens qualitatively different from that which occurs with most human asthma (leading to an ever-expanding search for the ideal allergic model), species differences in the expression or function of numerous airway genes important in the asthma phenotype, and difficulty in measuring certain features of asthma (including both lung function and AR) due to either size or anatomic differences (141, 143, 145) . Although some differences are less important for assessing AHR (regardless of the effect of AR on this feature), the study of AR per se is considerably more problematic. Although many features of AR observed in humans can be induced in the mouse, such induction typically occurs much more rapidly in mouse models, coinciding with the short and intense sensitization/challenge to allergen used in most protocols. Although this compressed time frame of AR development is cost saving, it does not replicate the slowdeveloping nature of AR in humans involving persistent as well as intermittent exacerbating stimuli. Although an attenuated and extended duration protocol in the mouse is possible, the trade-off appears to be more modest AHR. Perhaps most problematic with the mouse model for AR research is airway architecture, where, unlike the more than 20 levels of dichotomous branching of conducting airways in humans leading to respiratory bronchioles, after the large conducting airways, the monopodial branches of the mouse airways quickly transition into terminal bronchioles and alveolar ducts. It is likely that this very different architecture influences the response to both the physical forces and (localized) inflammatory factors that promote AR. Conversely, the effect of localized AR and resultant airway narrowing and AHR on other lung areas also likely differ. And, finally, the lack of murine transgenic or knockout models that regulate specific AR attributes has greatly hindered our ability to link such attributes to physiologically relevant outcomes.
Several studies have successfully examined features of AR using other animal models of asthma, including the rat (146-156), guinea pig (11, (157) (158) (159) (160) (161) (162) (163) (164) (165) , dog (166) (167) (168) (169) (170) (171) , horse (172) (173) (174) (175) (176) , and nonhuman primate (177) . Larger animals, by simple virtue of their size, are obviously better models when assessing morphology changes, yet many of the same issues (species differences in genome, lung architecture) remain in these models. Here, the lung architecture of the dog may be closer to the human, but gravitational effects due to postural differences may be limiting. Conversely, the guinea pig is often used as a model of AHR (particularly when examining neural influences) and has evidence for AR. Moreover, the cost of working with larger animals is understandably greater, and given that asthma (and AR) phenotyping does not lend itself to longitudinal analysis, the need for population-based analyses over time to obtain AR data often makes studies with larger animals cost prohibitive.
Given the above limitations of animal models, human studies of AR of course represent the gold standard model of asthma, yet they are difficult to perform due to the numerous methodological, logistical, and economic issues, as discussed below. design human studies testing a potential anti-AR intervention given the lack of consensus of which AR index is important (or responsive to therapy), the difficulty (including cost) and feasibility of measuring accurately and sensitively any AR index in a large number of subjects, the difficulty in justifying any intervention specific for AR without compromising the Protection of Human Subjects, and the need to preserve the objectives and enrollment of any study testing another intervention where an anti-AR drug might be tested as an adjunct.
METHODOLOGICAL LIMITATIONS WITH RESPECT TO PROTOCOLS AND TECHNIQUES
IT IS DIFFICULT TO PROPOSE "DELIVERABLES" FOR RESEARCH TESTING ANY ANTI-AR DRUG. This point is explained in part by point 7 immediately above and the fact that much of AR research remains "basic" (i.e., identifying indices of interest, quantification of such indices, establishing upstream and downstream mechanisms, and overall exploring functional outcomes). In contrast, few studies examine strategies to prevent or reverse AR overall. More recently, some studies have identified anti-remodeling effects of certain agents, such as long-acting b 2 agonists (187, 188) or bitter tastants (189) , but these studies remain preclinical and have not even started to explore AR in the context of age and disease severity. Bronchial thermoplasty, a relatively new procedure resulting in sustained improvement of asthma symptoms (190, 191) , is proposed to reduce the exaggerated amounts of ASM in the asthmatic airway; however, systematic studies to demonstrate blunting of AR are lacking.
The many hurdles limit the peer review assessment of "impact" of AR research and competitiveness for funding. With respect to NIH or other major funding agencies, grant proposals focused on exploring AR mechanisms, or avenues to target AR, carry with them the many limitations discussed above. The lack of relevant human data that causatively tie AR to AHR, inflammation, and other recognized features of asthma limits the ability to successfully argue the "significance" aspect of an AR proposal. The multiple features of AR, and a lack of consensus regarding which are important from mechanistic or therapeutic perspectives, further reduce enthusiasm for the significance of a proposal and frequently lead to lack of enthusiasm of any otherwise coherent, focused, and innovative "approach." Here, the inherent limitations in studying a slow, progressive phenomenon blunt the appeal and feasibility of the "approach," a problem not unique to AR research but nonetheless difficult to circumvent. The lack of methodologies/tools-especially imaging tools-also limits diversity in "approach" and further limits "innovation." As a result, AR research may be seen as less "impactful" due to a limited ability to "translate" fundamental discovery research into preclinical/clinical research in the immediate or short term and ultimately leads to clinical trials and/or approved drugs (discussed further below). In the context of an extremely competitive funding environment, these limitations are difficult to overcome, and, as a consequence, AR grants would be expected to fare poorly in peer review settings where imminent deliverables from grants are expected. Again, although this issue is not unique to AR-focused grants, and indeed not even to remodeling in other organ systems, it is possible that AR research per se faces more numerous and significant limitations in terms of definition, methodology, impact, etc., that places this field at a relative disadvantage.
Priorities for AR Research
Certainly, given the broad, multifaceted, longitudinal nature of AR and the many hurdles identified above, it is important to delineate priorities in AR research areas that would most likely lead to logistically feasible and actionable avenues for drug development and therapeutic intervention. We propose the following priorities:
1. Agree on definitions and indices for AR overall and explore the importance of indices in age-, sex-, and etiologyspecific contexts of asthma, thus establishing the platform for mechanistic exploration of AR induction, maintenance, and progression. 2. Identify biomarkers, or nonlaborious indicators of AR, to facilitate comparisons to asthma phenotype data. Here, it would be important to identify the appropriate patient populations across the age and etiology spectrum for asthma that would most likely manifest AR, particularly early in disease.
Encourage clinical studies that establish
what features of AR cause or exacerbate features of asthma that are regulatory indicators (airflow obstruction, AHR, resolution of inflammation, and inflammatory markers), thus enhancing the interest of industry partners toward AR-focused drug development. 4. Given that AR can occur early in disease, perhaps even before overt symptoms, explore whether prophylaxis of AR in asthma is even feasible, thus identifying "at-risk" populations, aided by research using genetic and phenotypic markers.
Specific Issues That Hinder AR Drug Development and Approval
There exists a mutual reinforcing relationship among the difficulties in mechanistic bench AR research, clinical studies focusing on AR aspects of asthma, and AR drug development/approval. Thus, some points below incorporate concepts already articulated above.
Much of AR research is still in the "discovery stage". Indeed, given the broad definition of AR and the cell types involved, both upstream and downstream targets and mechanisms are not clearly established, thus making it somewhat premature and quite difficult to propose and design interventional or prophylactic basic or clinical research. Consequently, human trials of anti-AR drugs are also premature and difficult to justify.
Economic, particularly regulatory, issues thwart the appeal and feasibility of anti-AR drug discovery and trials. PERSPECTIVE OF DRUG AND THERAPY REGULATORY BODIES. Current Food and Drug Administration (FDA) regulatory indications for first approval of asthma medications include: (1) FEV 1 (a surrogate marker of disease), (2) signs and symptoms, and (3) decreased exacerbation rate over a clinically meaningful period (e.g., over 1 yr). None of these indications links directly and specifically to a change in histopathology within the airway. What is unfortunate is that any drug that meets current regulatory indications is examined post hoc in the research community for relevance to AR, without necessarily a strategic plan toward assessing the anti-AR potential of such therapies. A similar pattern of expectations has been noted by regulatory agencies within the European Union. This makes critical the identification of AR indices or biomarkers that serve as acceptable regulatory indications. Given the recent history of the FDA to deny approval of any new regulatory indication for asthma, such an advance appears unlikely. Accordingly, in the near and possibly extended future, anti-AR drugs will need to be examined for their ability to impact current indications. The hope, of course, is that educational measures, including progress in AR research, prompt regulatory agencies to reconsider and expand regulatory indications.
PERSPECTIVE OF THE PHARMACEUTICAL
INDUSTRY. Regulatory issues factor into calculation by this industry regarding the value of AR research and the need for industry-supported efforts to develop an anti-AR drug. The impact of absent regulatory indications related to AR and lack of interest of pharma/biotech to invest in anti-AR drugs is suggested by: (1) the lack of mention of any potential anti-AR effects of existing asthma/COPD drugs, (2) the lack of in-house research by pharma/biotech on anti-AR effects of existing or pipeline drugs, (3) minimal industry funding of AR research within academia. In this regard, three elements of an adequate risk-mitigation strategy are a prerequisite for undertaking novel drug development. First, the regulatory indication must be known and agreed on. Second, the intermediate proof of concept should be well defined in terms of duration and endpoint. Third, the commercialization strategy should be agreed on; it will not be possible to commercialize a drug for asthma that requires biopsy proof of efficacy.
To initiate anti-AR focused therapies, there is the need to establish a regulatory precedent that defines the clinical trial program for a new drug candidate. Before initiating drug or biologic development, there is a meeting between representatives of the sponsor and regulatory authority (e.g., FDA), which, even before the first human data are generated, outlines the goals of the program, including the initial indication. FEV 1 improvement has been well defined for decades at 15%. Improved signs and symptoms over 3 months has created a cottage industry of validated diaries to capture cough, wheeze, shortness of breath, sputum, nocturnal awakenings, and home-base measures of rescue medication usage and pulmonary function reporting. Reduction in exacerbations has more recently been accepted for two classes of drugs that failed to meet the accepted criteria. Risk mitigation is critical for pharma and especially so for innovative biotechnology companies. Bronchodilation can typically be demonstrated in a single dose and sustained bronchodilation within a few weeks. For drugs/biologics that do not improve FEV 1 predictably, improvement in signs and symptoms can be shown in clinical trials 4 to 6 weeks (less than 2 mo) in duration, certainly a more expensive path to risk mitigation but now defined. Subsequent longer-term ("chronic") indications, such as cost-effectiveness, or steroid sparing could be developed to extend a profitable franchise. Reduction in exacerbations as a primary indication reflects three products (anti-IL-5 monoclonal antibody, roflumilast, and anti-IgE) with massive expenditure and (unacceptably) long development histories that failed to achieve the accepted endpoints in prior adequate and wellcontrolled clinical trials. These are substantial barriers for anti-AR drugs, given lack of a regulatory indication; the difficulty of proof of concept in terms of a long, slow process of yet-undefined endpoint; and thus lack of a commercialization strategy that would be appealing to pharma and unlikely to be accepted by regulatory agencies.
OTHER ECONOMIC FACTORS. In addition to the confounding regulatory issues noted above, the inherent difficulties in performing human research/trials, their cost, and the reality that more potentially lucrative drugs may be competing for the eligible subject pool represent additional economic factors that hinder anti-AR drug development and approval. ∘ Enhance cross-fertilization of bench and clinical research information on remodeling in other organ systems and disease conditions, including, heart, kidney, liver, and skin. 3. Work with leading federal and foundation-based funding agencies as well as the pharmaceutical industry to emphasize the need and potential impact of AR-focused research toward development of supportive peer-review strategies that will expand the portfolio of grants and research efforts in this area. 4. Improve the design of human studies of AR. One means for such improvement might be to identify specific patient populations that will serve as more useful models for clinical research into AR. Ideally, the disease status of these patients will make them either prone to or protected from AR and, accordingly, responsive or resistant to any therapy. In this manner, effect sizes for experimental endpoints may be large, thus favoring statistical power. Possibilities include focusing on patient populations with specific Th2 profiles that are more or less likely to have AR, profiling based on steroid sensitivity/insensitivity (severe, persistent asthma), etiology (atopic versus occupational), age, and/or sex. Of particular interest are data suggesting certain elite athletes (particularly those with high ventilatory demands training in noxious environments [192, 193] ) are susceptible to rapid development of AR, suggesting that these populations may enable a study design in which the factors that promote pathology or potential anti-AR drugs could be tested over shorter, financially viable durations. Understanding AR mechanisms and their impact on disease is key to development of anti-AR therapies. However, significant barriers exist due to limitations in our ability to define the AR parameters to study, lack of appropriate tissue samples or longitudinal sampling approaches for a slowly progressing process, lack of biomarkers for AR, technological limitations in noninvasively assessing AR, and overall lack of enthusiasm from funding agencies, regulatory agencies, and the pharmaceutical industry in pursuing a protracted approach for a process with unclear regulatory indications. Nonetheless, given the emerging and increasingly established importance of AR in asthma, there need to be clear educational, research, funding, and regulatory advancements toward enhancing research into AR and development of novel therapies to blunt this process. Via this Research Statement, we have provided specific recommendations to achieve these goals. n This official research statement was prepared by a working group of the ATS Assembly on Respiratory Structure and Function.
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